• Announced on October 2nd, the US Department of Health and Human Services (HHS) has allocated the first funding under Project BioShield for Ebola countermeasures.
    This funding will add add two vaccines and two treatments to the Strategic National Stockpile (SNS): a single-dose vaccine licensed by Merck, a prime-boost vaccine regimen from Johnson & Johnson, and monoclonal antibody treatments from Mapp Biopharmaceutical and Regeneron Pharmaceuticals.
    The $170.2 million in Project BioShield funds covers late-stage development and buys up to 1.13 million vaccine regimens and an unspecified number of treatment courses of the two drugs.

  • Marine Fighter Attack Squadron 251, also known as the “Thunderbolts”, stationed at Marine Corps Air Station Beaufort, South Carolina, continue to showcase unit readiness through training for every possible scenario, while forward deployed to MCAS Iwakuni, Japan.

    The Thunderbolts have intensified training on familiarizing aircrew members with the Joint Protective Aircrew Ensemble (JPACE) and respirator, a pilot’s Chemical Biological Radiological Nuclear Defense equipment, while still maintaining focus on the squadron’s mission.

  • The National Library of Medicine (NLM) has added material to its online toxicology tutorial, ToxTutor. The new sections cover Basic Physiology, an Introduction to Toxicokinetics, Absorption, Distribution, Biotransformation, Excretion, and Cellular Toxicology.

  • Yesterday the Director-General of the Organisation for the Prohibition of Chemical Weapons (OPCW), Ambassador Ahmet Üzümcü of Turkey, congratulated Russia on completing the destruction of its chemical weapon stockpile which originally totaled 39967 agent tonnes (i.e., excluding munition weight). This represents a major milestone towards realizing a world without chemicals weapons as envisaged by the negotiators of the 1993 Chemical Weapons Convention’s (CWC).

  • Arktis, a leading provider of radiological and nuclear detection services, formally announced its strategic partnership with key industry stakeholders, launching Team Arktis. The launch of Team Arktis is part of the company’s mission to enhance the radiological and nuclear solutions it provides to the U.S. Government, and ensure a robust, high-volume US supply chain as well as be part of a domestic national security platform.

  • Emergent BioSoultions has been awarded another large contract, their fifth this year, worth $63 million to develop an antidote spray device for the treatment of known or suspected acute cyanide poisoning.
    This single-use intranasal spray device will deliver a stabilized form of isoamyl nitrite (SIAN) and is intended for use by first responders and medical personnel following a cyanide incident.
    “Emergent has a successful history of developing medical countermeasures that address the U.S. government’s top priority public health threats,” said Sean Kirk, senior vice president, manufacturing operations and interim head, devices business unit at Emergent BioSolutions. “We are committed to fulfilling BARDA’s requirements for an easily-administered treatment for acute cyanide poisoning, in collaboration with Southwest Research Institute. The development of the intranasal SIAN device will expand the company’s portfolio of novel devices to combat chemical threats. We are excited about the potential of this product candidate to meet the needs of both the government and commercial markets.”
    The contract is for a period of five years and will involve collaboration with Southwest Research Institute in order to advance the development of SIAN towards licensure.

  • Safety solutions provider Survitec is launching its new Sonics Bio Skin and Bio Shell protective suits – designed in conjunction with Gore with the CBRN market in mind – at DSEI in London next week

  • Opec CBRNe, the new name for Remploy Frontline products, snags preferred ensemble for Australian government

  • Decon7 are helping the good folks in the Houston Police Department by donating a large pallet of products to them so that they can safely decontaminate the uniforms, equipment, and vehicles that have been contaminated by flood waters due to Hurricane Harvey. Their staff worked late to ensure the products were packed and ready to be shipped as soon as possible, they also sent a message of support with ‘Stay Strong Houston’ written on the side of the pallet. Well done Decon7.

  • In a press release issued on its website on Septmeber 1st Sanofi Pasteur announced they will no longer be continuing with their Zika vaccine project.
    The announcement comes after the company was informed by the The Biomedical Advanced Research and Development Authority (BARDA) that, after an assessment of all Zika-related projects they are funding they have decided to focus on a more limited set of goals and deliverables. As a result of the review Sanofi Pasteur was notified of BARDA’s decision to “de-scope” its contract with Sanofi Pasteur to fund the manufacture and clinical development of an inactivated Zika vaccine and will limit its funding.

    Consequently, Sanofi does not intend to continue development of, or seek a license from, the Walter Reed Army Institute of Research for the Zika vaccine candidate at this time.

  • Follow us on Twitter
  • Subscribe to CBRNe news